San Diego, Sept.30, 2024 – EpicentRx, a clinical stage biopharmaceutical company with strong momentum and big plans, will present compelling preclinical data on lead small molecule, RRx-001 (nibrozetone), in Parkinson’s Disease (PD) at the 2024 International Congress of Parkinson’s Disease and Movement Disorders (MDS).
Dr. Richard Gordon, A/Prof. from the Queensland University of Technology’s Translational Research Institute (QUT-TRI), will deep dive into the anti-Parkinsonian activity of RRx-001 during a one-hour platform presentation at MDS in Philadelphia, PA.
The MDS annual meeting, which gathers thousands of neurologists and neuroscientists from around the world, is a premier venue for Dr. Gordon and EpicentRx to present their research on RRx-001 and to showcase its one-of-a-kind antioxidative and anti-inflammatory activity. The presentation titled “Validating the clinical stage NLRP3 inflammasome inhibitor RRx-001 (nibrozetone) as a disease-modifying therapeutic for Parkinson’s disease,” is scheduled for the Group 2 Pharmacology section on Saturday September 28 from 1:30-2:30 pm EST.
EpicentRx and Dr. Gordon have been awarded several prestigious grants from the Michael J. Fox Foundation, the US Department of Defense (DoD) and others to investigate the activity of lead EpicentRx small molecule, RRx-001 (nibrozetone), in several ND indications including Parkinson’s, Amyotrophic Lateral Sclerosis (ALS)/Motor Neurone Disease (MND), and central nervous system (CNS) toxic exposures.
About EpicentRx:
EpicentRx Incorporated is a privately held biopharmaceutical company with two innovation-driven platforms of which nibrozetone (RRx-001) and AdAPT-001 are the lead compounds, respectively. The company’s mission is disease remission, which it hopes to accomplish with novel, well-tolerated therapies that target a diverse range of unmet needs in cancer and non-cancer indications. Nibrozetone (RRx-001), a multimechanistic small molecule is designed and currently under clinical investigation to preferentially target diseased tissues like tumors even as it shields normal cells from harm. A late-stage clinical trial named KEVLARx is currently ongoing for protection against chemoradiation-induced oral mucositis in first line head and neck cancer. Learn more at https://www.epicentrx.com.
Media Contact:
Ashley Thomaz
Email: ashleyt@mcspr.com